Flucytosine-miconazole treatment of Candida peritonitis. Its use during continuous ambulatory peritoneal dialysis.
A case of Candida parapsilosis peritonitis occurred in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD). Treatment with oral doses of flucytosine and intravenous doses of miconazole was effective. No interruption in CAPD was necessary, and acceptable flucytosine levels were obtained in the serum and dialysate. This case and information available in the literature suggest that Candida peritonitis can be treated effectively with antimicrobial agents that are well tolerated by the patient, and removal of the dialysis catheter is not always necessary for cure.
D002177:Candidiasis / Q000188:drug therapy* / Q000209:etiology; D003596:Cytosine / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D005437:Flucytosine / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000628:therapy; D008825:Miconazole / Q000627:therapeutic use*; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology
D007093:Imidazoles; D008825:Miconazole; D003596:Cytosine; D005437:Flucytosine